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Abstract
Olanzapine is widely used in treating multiple domains of schizophrenia symptoms but induces serious
metabolic side-effects. Recent evidence has showed that co-treatment of betahistine (a histaminergic H1
receptor agonist and H3 receptor antagonist) is effective for preventing olanzapine-induced weight gain/
obesity, however it is not clear whether this co-treatment affects on the primary therapeutic receptor binding
sites of olanzapine such as serotonergic 5-HT2A receptors (5-HT2AR) and dopaminergic D2 receptors
(D2R). Therefore, this study investigated the effects of this co-treatment on 5-HT2AR, 5-HT transporter
(5-HTT) and D2R bindings in various brain regions involved in antipsychotic efficacy. Female Sprague
Dawley rats were administered orally (t.i.d.) with either olanzapine (1 mg/kg), betahistine (2.7 mg/kg),
olanzapine plus betahistine (O + B), or vehicle (control) for 2 weeks. Quantitative autoradiography was used
to detect the density of [3H]ketanserin, [3H]paroxetine and [3H]raclopride binding site to 5-HT2AR,
5-HTT and D2R. Compared to the controls, olanzapine significantly decreased [3H]ketanserin bindings to
5-HT2AR in the prefrontal cortex, cingulate cortex, and nucleus accumbens. Similar changes in 5-HT2AR
bindings in these nuclei were also observed in the O + B co-treatment group. Olanzapine also significantly
decreased [3H]paroxetine binding to 5-HTT in the ventral tegmental area and substantia nigra, however, both
olanzapine only and O + B co-treatment did not affect [3H]raclopride binding to D2R. The results confirmed
the important role of 5-HT2AR in the efficacy of olanzapine, which is not influenced by the O + B co-
treatment. Therefore, betahistine co-treatment would be an effective combination therapy to reduce
olanzapine-induced weight gain side-effects without affecting olanzapine's actions on 5-HT2AR
transmissions.
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Abstract 
Olanzapine is widely used in treating multiple domains of schizophrenia symptoms but 
induces serious metabolic side-effects. Recent evidence has showed that co-treatment of 
betahistine (a histaminergic H1 receptor agonist and H3 receptor antagonist) is effective for 
preventing olanzapine-induced weight gain/obesity, however it is not clear whether this co-
treatment affects on the primary therapeutic receptor binding sites of olanzapine such as 
serotonergic 5-HT2A receptors (5-HT2AR) and dopaminergic D2 receptors (D2R). Therefore, 
this study investigated the effects of this co-treatment on 5-HT2AR, 5-HT transporter (5-HTT) 
and D2R bindings in various brain regions involved in antipsychotic efficacy. Female 
Sprague Dawley rats were administered orally (t.i.d.) with either olanzapine (1mg/kg), 
betahistine (2.7mg/kg), olanzapine plus betahistine (O+B), or vehicle (control) for 2-weeks. 
Quantitative autoradiography was used to detect the density of [3H]ketanserin, [³H]paroxetine 
and [3H]raclopride binding site to 5-HT2AR, 5-HTT and D2R. Compared to the controls, 
olanzapine significantly decreased [3H]ketanserin bindings to 5-HT2AR in the prefrontal 
cortex, cingulate cortex, and nucleus accumbens. Similar changes in 5-HT2AR bindings in 
these nuclei were also observed in the O+B co-treatment group. Olanzapine also significantly 
decreased [³H]paroxetine binding to 5-HTT in the ventral tegmental area and substantia nigra, 
however, both olanzapine only and O+B co-treatment did not affect [3H]raclopride binding to 
D2R. The results confirmed the important role of 5-HT2AR in the efficacy of olanzapine, 
which is not influenced by the O+B co-treatment. Therefore, betahistine co-treatment would 
be an effective combination therapy to reduce olanzapine-induced weight gain side-effects 
without affecting olanzapine’s actions on 5-HT2AR transmissions. 
 
Keywords: Olanzapine, betahistine, receptor binding, 5-HT2A receptor, 5-HT transporter, 
dopamine D2 receptor 
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1. Introduction 
Second generation antipsychotic drugs (SGAs) such as olanzapine have been used not only to 
ameliorate schizophrenia symptoms but also used widely for other mental disorders such as 
bipolar disorder, depression, and Tourette’s syndrome (Lambert, 2011). However, these 
drugs could induce serious metabolic side-effects including body weight gain and obesity 
(Allison et al., 1999, Stahl et al., 2009, Correll et al., 2011). In contrast to first generation 
antipsychotic drugs (FGAs) (e.g. chlorpromazine and haloperidol) as a potent dopamine D2 
receptor (D2R) antagonist, SGAs (such as olanzapine) have high affinities to not only D2R 
but also to a wide range of non-dopaminergic G-protein-coupled receptors, including 
histaminergic H1 (H1R), serotonergic 5-HT2A (5-HT2AR) and 5-HT2C (5-HT2CR), muscarinic 
M1 (M1R) and adrenergic α1-2 (α1-2R) receptors (Richelson and Souder, 2000, Nasrallah, 
2008). The binding affinities of olanzapine to these neurotransmitter receptors are ranked in 
the following order: H1R>5-HT2R>D2R>αR and M1R (Uchida et al., 2007). Since a number 
of studies have shown that H1R plays a key role in olanzapine induced weight gain/obesity 
(Kim et al., 2007, Han et al., 2008a, Deng et al., 2010, He et al., 2013), H1R could be a 
therapeutic target for controlling olanzapine-induced weight gain side-effects. Recently we 
found in a rat model that olanzapine-induced weight gain can be partially reduced (-45%) by 
co-treatment with betahistine (an H1R agonist and H3R antagonist) (Deng et al., 2012).  This 
finding was confirmed by a recent clinical report that schizophrenia patients with a 
combination treatment of olanzapine, betahistine and reboxetine (a selective norepinephrine 
reuptake inhibitor) had significantly less weight gain than those on olanzapine only 
(Poyurovsky et al., 2013). In addition, a small clinical trial with 3 first episode schizophrenic 
patients also found that betahistine was able to prevent weight gain related to olanzapine 
treatment (Poyurovsky et al., 2005). Therefore, current evidence confirms the potential of 
betahistine in preventing the weight gain/obesity side-effect caused by olanzapine and 
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possibly other SGAs. One important issue that should be addressed, however, is whether co-
treatment of olanzapine and betahistine affects the antipsychotic efficacy of olanzapine.  
 
D2R is proven to be a key receptor for the pathophysiology of schizophrenia and the 
therapeutic effects of antipsychotic drugs (Kapur et al., 1999, Kapur and Mamo, 2003, Stahl, 
2003, Volk, 2010, Seeman, 2011), and also plays an important role in the reward function 
(Volkow et al., 2011). Dopaminergic neurons have major projections derived from the 
mesencephalon including (1) the nigrostriatal pathway, in which the substantia nigra (SN) 
projects to the caudate putamen (CPu); (2) the mesolimbic pathway, in which the ventral 
tegmental area (VTA) projects to the nucleus accumbens (NAc); and (3) the mesocortical 
pathway, in which the VTA projects to the cortex including the PFC and Cg (Kapur and 
Mamo, 2003, Volk, 2010). Accumulated evidence suggests that D2R is the common target for 
all of current antipsychotics (Kapur et al., 1999, Kapur and Mamo, 2003, Seeman, 2011). On 
the other hand, it has been proposed that a relatively higher 5-HT2AR affinity compared to the 
D2R is the mechanism underlying the therapeutic effects of SGAs (Meltzer et al., 2003, 
Horacek et al., 2006, Kuroki et al., 2008, Meltzer and Massey, 2011). Serotonin neurons are 
located in the raphe nuclei which broadly project to various brain regions and exert their 
actions via various types of 5-HT receptors (Millan et al., 2008). Among them, 5-HT2AR 
plays a critical role in the action of SGAs such as olanzapine (Meltzer and Massey, 2011). 
Moreover, the clinical data showed that there was decreased 5-HT2AR binding in the 
prefrontal cortex (PFC), and cingulated cortex (Cg), superior temporal gyrus and striatum in 
post-mortem brains of schizophrenia patients treated by SGAs (Matsumoto et al., 1996, Scarr 
et al., 2004, Steward et al., 2004, Kang et al., 2009).  
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Furthermore, the blockade of 5-HT2AR by olanzapine could contribute to the 5-HTergic 
modulation on the nigrostriatal,  mesolimbic or mesocortical dopaminergic pathways which 
affects dopaminergic output in the NAc, CPu, PFC and Cg  (Van Oekelen et al., 2003, 
Horacek et al., 2006) and D2R mediated neurotransmission (Meltzer and Massey, 2011). 
Therefore, due to the critical roles of 5-HT2AR and D2R in the therapeutic effect of SGAs, 
this study examined the effects of olanzapine and/or betahistine treatment on 5-HT2AR, and 
D2R bindings in the key brain regions for therapeutic effect of SGAs. In addition, the binding 
density of serotonin transporter (5-HTT) has also been examined. 
 
2. Methods 
2.1. Animal treatment and administration  
Female Sprague Dawley rats (201-205g) were obtained from the Animal Resources Centre 
(Perth, WA, Australia).  After one week of environmental familiarisation, they were housed 
in individual cages and allowed ad-libitum access to water and standard laboratory chow diet  
(3.9 kcal/g; 10% fat, 74% carbohydrate and 16% protein) under environmentally controlled 
conditions (22°C, light cycle from 07:00 to 19:00 and dark cycle from 19:00 to 07:00) 
throughout the whole study (Han et al., 2008a, Deng et al., 2012, Weston-Green et al., 2012). 
Rats were randomly administered different drugs 3 times per day orally (07:00, 15:00, 23:00 
h) (n=12) for two weeks: (1) olanzapine only (1mg/kg, Eli Lilly, USA), (2) betahistine only 
(2.67 mg/kg, Manus Aktteva, India), (3) combined olanzapine and betahistine (O+B), or (4) 
control (vehicle) (Deng et al., 2012). Drugs were prepared in advance by mixing with cookie 
dough pellets (0.3g; including 30.9% cornstarch, 30.9% sucrose, 6.3% gelatine, 15.5% 
casein, 6.4% fibre, 8.4% minerals and 1.6% vitamins) and droplets of water (Han et al., 
2008a, Deng et al., 2012, Weston-Green et al., 2012). The equivalent pellet without drug was 
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used as controls. Prior to the drug treatment, rats were trained with cookie-dough pellets 
without any drug for one week.  The half life of olanzapine in rats is 2.5 and 5.1 h in the 
plasma and brain respectively, however the drug concentration maintains a high level after 8 
h in the rat brain, compared with the half-life of 24.2 and 72 h in human plasma and brain 
(Aravagiri et al., 1999, Tauscher et al., 2002). Therefore, 8 hour intervals were chosen in the 
present study in order to maintain the high concentration of olanzapine and to mimic clinical 
administration (Deng et al., 2012). All experimental procedures have been approved by the 
Animal Ethics Committee, University of Wollongong, Australia (AE11/10); and complied 
with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
(2004). Body weight and energy intake data have been reported previously that, in brief, 
olanzapine only treatment induced significant body weight gain and increased food intake, 
while co-treatment of olanzapine with betahistine significantly prevented (-45%) weight gain 
and reduced feeding efficiency compared to sole olanzapine treatment (Deng et al., 2012). 
Six brains from each group were used for binding experiments. 
 
2.2. Histological procedures 
All rats were sacrificed using carbon dioxide asphyxiation, and then brains were removed and 
frozen in liquid nitrogen immediately followed by storage in a -80 °C freezer until sectioning. 
Brains were cut at -18 °C into 14 μm coronal sections using a cryostat (Leica CM1850, Leica 
Microsystems, Germany). The corresponding brain regions were obtained based on a 
standard rat brain atlas (Paxinos and Watson, 2007) (Figure 1). Brain sections were thaw-
mounted onto Polysine™ Microscope Slides (Menzel GmbH & Co. KG, Braunschweig, 
Germany) and stored at -20 °C. A set of sections from each animal was stained with 0.5% 
cresyl violet solution (Nissl staining) and used for confirmation of anatomical structures. 
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2.3. Receptor binding autoradiography and quantification 
The procedures for the 5-HT2AR, 5-HTT, and D2R binding autoradiography have been 
reported previously (du Bois et al., 2006, Huang et al., 2006b, du Bois et al., 2008, Kang et 
al., 2009, Kesby et al., 2012). 
 
2.3.1. 5-HT2AR binding procedures 
In brief, brain sections containing the PFC, Cg, NAc, CPu, VTA, and SN were thawed at 
room temperature (RT), and after 15 min of pre-incubation in 170 mM Tris buffer (pH 7.4), 
they were incubated with 2nM [³H]ketanserin (Specific activity: 67 Ci/mMol; PerkinElmer, 
USA) in 170 mM Tris buffer for 2 h at RT to determine total binding of 5-HT2AR. Non-
specific binding was determined by incubating the next sequential sections with 2nM 
[³H]ketanserin incubation buffer, with the addition of 2μM spiperone (Sigma 
Pharmaceuticals, Australia). Slides were washed twice for 10 minutes in ice-cold buffer, 
dipped in ice-cold distilled water, and then dried under a stream of cool air to remove excess 
buffer salts (du Bois et al., 2006, Kang et al., 2009).  
 
2.3.2. 5-HTT binding procedures 
Binding of [³H]paroxetine (specific activity: 20.8 Ci/mmol, PerkinElmer, USA) to 5-HTT 
was performed based on procedures previously described (du Bois et al., 2006). In brief, 
sections were pre-incubated in 50 mM Tris buffer including 120 mM NaCl and 5 mM KCl 
(pH 7.4) for 15 min at RT. Sections were then incubated for 2 h at RT in the same buffer 
containing 0.6 nM [³H]paroxetine for the total binding. Non-specific binding was determined 
with the addition of 10 μM fluoxetine. After incubation, the sections were washed in ice-cold 
buffer (2×10 min), dipped in distilled water and air dried (du Bois et al., 2006). 
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2.3.3. D2R binding procedures 
In terms of the D2R binding, the 50 mM Tris buffer added with 120 mM NaCl, 5 mM KCl, 2 
mM CaCl2, 1mM MgCl2 and 0.001% ascorbic acid (pH 7.4) was applied for a pre-incubation 
period of 30 min. Furthermore, 5 nM [3H]raclopride (specific activity: 60.1 Ci/mmol; 
PerkinElmer, USA) was used for total D2 receptor binding during 1 h of incubation, while 
non-specific binding was determined by 10 μM butaclamol and 5 nM [3H]raclopride using 
the same buffer. After incubation, the slides were washed with the cold buffer (2×5 min), 
dipped in distilled water and air dried (Huang et al., 2006b, du Bois et al., 2008, Kesby et al., 
2012). 
 
2.3.4. Quantification  
The receptor binding image was captured using a Beta-imager™ 2000 (BioSpace, Paris, 
France) with a high-resolution setting and scanned for 3.5 hours. One slide with a known 
amount of radioactivity was used as a standard (Deng et al., 2007, Kang et al., 2009). The 
level of bound radioactivity in the brain sections was determined by directly counting the 
number of β-particles emitted from the tissue, which was analysed using a Beta Vision Plus 
programme (Version 4, BioSpace, Paris, France). The radioligand binding signal was 
converted from counts per minute per square millimetre (cpm/mm²) to nanocuries per 
milligramme (nCi/mg) of tissue equivalent (nCi/mg TE) (Deng et al., 2007, Kang et al., 
2009). Specific binding was calculated by subtracting non-specific binding from total 
binding. Specific brain regions in this project were identified by reference to the Nissl-stained 
sections and a standard rat brain atlas (Paxinos and Watson, 2007).  
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2.4. Statistical analysis 
Statistical analysis was performed using SPSS (IBM version 19.0, SPSS Inc., USA). Two-
way ANOVAs (OLANZAPINE × BETAHISTINE) were used to analyse receptor binding 
density in relevant brain regions of the rat. The post-hoc Dunnett-T tests were followed for 
comparison between groups. All data are expressed as mean ± SEM, and statistical 
significance will be accepted when p<0.05.  
 
3. Results 
3.1. 5-HT2AR binding 
Examples of [³H]ketanserin binding to 5-HT2AR are presented in Figure 1 (A’-C’). Two-way 
ANOVAs revealed the significant main effect of OLANZAPINE factor in the PFC 
(F1,20=78.060, p<0.001), Cg (F1,20=66.025, p<0.001), NAcC (F1,20=14.574, p=0.001), and 
NAcS (F1,20=11.203, p=0.003), but no effect of the BETAHISTINE factor (all p>0.05) and 
also no significant interactions between the two factors in these brain regions (all p>0.05). 
Post-hoc analysis demonstrated that compared to the control (Figures 2 and 3), olanzapine 
significantly decreased the levels of 5-HT2AR binding density in the PFC (p<0.001), Cg 
(p<0.001), as well as NAcC (p<0.05) and NAcS (p<0.05). Similarly, the O+B co-treatment 
also significantly decreased 5-HT2AR binding density in the PFC (p<0.001; Figures 2 and 3), 
Cg (p<0.001), NAcC (p<0.01), and NAcS (p<0.05). However, olanzapine and betahistine had 
no effect on 5-HT2AR binding density in the CPu (Figure 3C) and VTA (Figure 3F). In the 
SN, although olanzapine had a lower 5-HT2AR binding than the control group, it was not 
significant (p>0.05; Figure 3F).  
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3.2. 5-HTT binding 
Examples of [³H]paroxetine binding to 5-HTT are presented in Figure 1 (A’’-C’’). Two-way 
ANOVAs revealed a significant effect of the OLANZAPINE factor on 5-HTT binding in the 
VTA (F1,20=9.728, p=0.005) and SN (F1,20=12.445, p=0.002), but no significant effect of the 
BETAHISTINE factor (all p>0.05) and also no significant interactions between the two 
factors in these brain regions (all p>0.05). Post-hoc analysis showed that, olanzapine 
treatment significantly decreased the 5-HTT binding density in the VTA (p<0.05) and SN 
(p<0.01) compared with control (Figure 4 E and F). O+B co-treatment tended to decrease 5-
HTT binding density in the SN (p=0.061; Figure 4F). In the VTA (Figure 4E), O+B group 
had a lower 5-HTT binding density than the control, but not significant (p>0.05). However, 
there were no significant differences between the control group and all drug treatment groups 
in other brain regions (Figure 4 A-D).  
 
3.3. D2R binding 
Examples of [3H]raclopride binding to D2R were presented in Figure 1 (A’’’-C’’’). Two-way 
ANOVAs found no significant effects of the OLANZAPINE and BETAHISTINE factors in 
all brain regions examined (all p>0.05). Moreover, no significant interaction between the two 
factors was detected in these brain regions (Table 1).  
 
4. Discussion 
This study investigated the effects of olanzapine and/or betahistine treatment on 5-HT2AR, 5-
HTT, and D2R binding density in the rat brain. Both olanzapine only and O+B co-treatment 
down-regulated 5-HT2AR binding density in various brain regions, including the PFC, Cg, 
NAcC and NAcS. In terms of the 5-HTT binding, compared with control, olanzapine 
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treatment significantly decreased the binding density in the VTA and SN. However, no 
significant effects of olanzapine and/or betahistine treatment were detected on D2R binding. 
    
It has been repeatedly reported that treatment with SGAs such as olanzapine and clozapine 
causes down-regulation of 5-HT2AR in receptor binding, protein level and mRNA expression, 
which  contributes to the therapeutic efficacy of these SGAs (Kusumi et al., 2000, Tarazi et 
al., 2002, Huang et al., 2006a, Kuroki et al., 2008, Yadav et al., 2011). Consistent with these 
reports, this study found that olanzapine only treatment decreased 5-HT2AR bindings in brain 
regions involved in antipsychotic therapeutics including the PFC, Cg, NAcC and NAcS 
(Tarazi et al., 2002, Cohen et al., 2003, Stahl, 2003, Yadav et al., 2011). It is important that 
O+B co-treatment caused the same down-regulation in 5-HT2AR binding density as 
olanzapine only treatment, while betahistine only treatment had no significant effects on 5-
HT2AR bindings in these brain regions. These results suggest that O+B co-treatment should 
have similar down-regulation effects on 5-HT2AR as olanzapine only treatment.  
    
Although several studies have identified an association between polymorphism of the 5-HTT 
gene and therapeutic effects of olanzapine in schizophrenia patients (Mata-Pastor et al., 2002, 
Bozina et al., 2007, Vazquez-Bourgon et al., 2010), it is not clear how 5-HTT contributes to 
the response to olanzapine treatment in schizophrenia. To our knowledge, this is the first 
study to examine the effects of olanzapine on 5-HTT bindings, in which we found olanzapine 
decreased 5-HTT bindings in the SN and VTA. O+B group had similar tendency in 
decreasing 5-HTT bindings in this region. This result suggests that olanzapine may act 
through modulating 5-HT uptake in the SN and VTA, two key regions for antipsychotic 
therapeutics (Stahl, 2003, Strange, 2008).   
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In this study, olanzapine treatment did not cause any significant changes in D2R bindings in 
all brain regions. This result confirmed previous reports that both short-term and chronic 
olanzapine treatment did not affect D2R bindings in the PFC, CPu and NAc (Kusumi et al., 
2000, Han et al., 2009a). Similarly it has been reported that SGAs with lower affinity to D2R 
such as clozapine and quetiapine did not affect D2R bindings, while antipsychotics with high 
D2R affinity such as haloperidol, chlorpromazine and risperidone have been reported to 
increase D2R bindings (Tarazi et al., 1997, Kusumi et al., 2000, Tarazi et al., 2001). These 
results are consistent with a PET study showing that olanzapine had a lower D2R blockade 
compared to haloperidol in schizophrenia patients (Xiberas et al., 2001). Although one study 
observed that olanzapine increased D2R density in the PFC, NAc and CPu of rats, much 
higher doses of olanzapine (5.0 mg/kg/day compared to 1 mg/kg, t.i.d. in this study) and 
osmotic minipumps were used in that study (Tarazi et al., 2001). However, a recent study has 
provided clear evidence that osmotic minipumps are not a suitable method for olanzapine 
delivery due to a rapid degradation of olanzapine in water solution (Remington et al., 2011). 
It is worth noting that olanzapine could modulate dopamine release in the PFC, NAc and CPu 
through 5-HT2AR  (Li et al., 1998, Marcus et al., 2000, Kuroki et al., 2008). In the PFC, 
experiments showed that 5-HT2AR and D2R blockage by olanzapine increased dopamine 
release via 5-HT1AR activation (Ichikawa et al., 2001), although in a recent study reported 
that olanzapine could increase dopamine release via 5-HT1AR activation in 5-HT2AR 
knockout mice (Bortolozzi et al., 2010). Therefore, although olanzapine treatment does not 
influence D2R binding, there should be interactions between 5-HT2AR and dopamine 
transmission (Kuroki et al., 2008). Furthermore, this is the first study to investigate the effects 
of betahistine on 5-HT2AR and D2R bindings. We found that O+B co-treatment and 
betahistine only treatment did not change D2R bindings in all brain regions examined, which 
suggests that O+B co-treatment does not influence the action of olanzapine on D2R 
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transmission. However, D2R can exist in a state of high-affinity (D2high) or in a state of low-
affinity for dopamine (D2low) (Seeman et al., 2006, Seeman, 2011). Normally, about 10-20% 
of D2R population is in the D2high state (Seeman, 2011). It has been reported that long-term 
treatment of antipsychotics generally increases D2R density by 10-40%, while it increases the 
proportion of D2high receptors by a factor of 2-4-fold (2-fold for 9-day treatment of 0.75mg/kg 
olanzapine) (Seeman et al., 2006). Therefore, it is important in further studies to investigate 
whether O+B co-treatment affects the proportion of D2high receptors.  
    
The animal model of olanzapine-induced weight gain has been well established and validated 
in female rats in our and other laboratories (Goudie et al., 2002, Choi et al., 2007, Weston-
Green et al., 2011, Deng et al., 2012). The sensitivity of female rats to weight gain side-effect 
over males is also a common observation in the clinic, where female patients have a much 
higher risk for weight gain side-effects associated with atypical antipsychotics (Gebhardt et 
al., 2009, Seeman, 2009, Weston-Green et al., 2010, Treuer et al., 2011). Furthermore, in this 
study, rats were closely housed in a room occupied by only female rats. Our pre-experiments 
have shown that, under this rearing condition, the estrus cycles of all female rats are 
synchronized (unpublished data). The olanzapine dosage used in this study (1 mg/kg, t.i.d.) 
has been shown to be pharmacologically effective in affecting central receptor systems 
relative to its pharmacological profile (Han et al., 2008b, Han et al., 2009a, Han et al., 2009b, 
Weston-Green et al., 2011), as well as behaviourally effective in affecting locomotor activity 
and food intake, and producing the obesity phenotype in rats (Han et al., 2008a, Weston-
Green et al., 2011, Deng et al., 2012). The dosage of betahistine (2.67 mg/kg, t.i.d.) is 
effective in reducing food intake during acute treatment (Szelag et al., 2001) and preventing 
olanzapine-induced weight gain in rats (Deng et al., 2012). According to dosage translation 
between species based on body surface area following an FDA guideline for clinical trials 
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(Center for Drug Evaluation and Research FDA, 2005, Reagan-Shaw et al., 2008), 1 mg/kg 
olanzapine in rats is equivalent to ~10 mg in humans (60kg body weight), and 2.67 mg/kg 
betahistine in rats to ~26 mg in humans; both are among the recommended clinical doses.  
 
5. Conclusions  
The present study provides the first evidence that O+B co-treatment has similar effects as 
olanzapine only treatment on the 5-HT2AR, 5-HTT and D2R bindings in key regions of the 
brain associated with antipsychotic therapeutics (Kapur and Mamo, 2003, Kuroki et al., 
2008). This study suggested that the co-treatment of olanzapine and betahistine could be a 
fair option for ameliorating the body weight gain/obesity side-effect without affecting 
olanzapine actions on 5-HT2AR and D2R transmissions. Consistently, a small clinical trial for 
6 weeks co-treatment of olanzapine and betahistine did not observed any interference with 
the antipsychotic effects of olanzapine (Poyurovsky et al., 2005). This was confirmed by a 6-
week trial of co-treatment of olanzapine and betahistine-reboxetine that did not interfere with 
olanzapine’s effect on core schizophrenia symptoms (Poyurovsky et al., 2013). It is important 
to investigate whether co-treatment of betahistine and other SGAs will have similar effects on 
weight gain, 5-HT2AR, 5-HTT and D2R bindings, as well as efficacy in controlling 
schizophrenia symptoms. 
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Table 1 Specific [3H]raclopride binding (nCi/mg tissue; mean values ± SEM; n=6/group) to 
D2 receptors in different brain regions following olanzapine and/or betahistine treatment. 
 
Group Control Olanzapine Betahistine O+B 
PFC 1.93 ± 0.10 2.17 ± 0.07 1.98 ± 0.17 1.81 ± 0.18 
Cg 3.13 ± 0.09 3.16 ± 0.10 3.24 ± 0.13 2.90 ± 0.11 
CPu 3.61 ± 0.11 3.73 ± 0.12 3.71 ± 0.15 3.56 ± 0.05 
NAcC 3.29 ± 0.13 3.41 ± 0.06 3.67 ± 0.17 3.26 ± 0.07 
NAcS 3.03 ± 0.09 3.11 ± 0.07 3.18 ± 0.11 3.02 ± 0.14 
SN 1.73± 0.11 1.69 ± 0.17 1.82 ± 0.09 1.48 ± 0.09 
VTA 1.81 ± 0.11 1.78 ± 0.17 1.85 ± 0.15 1.59 ± 0.10 
 
Abbreviations: Cg, cingulate cortex; CPu, caudate putamen; NAc, nucleus accumbens, 
core; NAs, nucleus accumbens, shell; O+B, olanzapine and betahistine co-treatment; 
PFC, prefrontal cortex; SN, substantia nigra; VTA, ventral tegmental area. 
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Figure Legends 
 
Figure 1 Examples of 5-HT2A, 5-HTT, and D2 receptor bindings in the rat brain. A-C, the 
schematic diagram is adapted from a rat brain atlas (Paxinos and Watson, 2007) showing the 
level of Bregma 3.72 mm (A), 1.08 mm (B), and -5.04 mm (C). A’-C’, examples of digital 
autoradiogram obtained with a Beta Imager to show [3H]ketanserin binding to 5-HT2A 
receptors. A’’-C’’, examples of [³H]paroxetine binding to 5-HTT.  A’’’-C’’’, examples of 
[3H]raclopride binding to D2 receptors. Abbreviations: Cg, cingulate cortex; CPu, caudate 
putamen; NAcC, nucleus accumbens, core; NAcS, nucleus accumbens, shell; PFC, prefrontal 
cortex; SN, substantia nigra; VTA, ventral tegmental area.  
 
Figure 2 Typical autoradiographs depict the binding densities of 5-HT2A receptors in the 
prefrontal cortex (PFC) of rats (n=6/group) treated with (A) vehicle (control), (B) olanzapine 
(Olan), (C) betahistine (Beta), and (D) olanzapine and betahistine co-treatment (O+B). 
Standard bar: min/max: 0-7 nCi/mg tissue equivalent. 
 
Figure 3 The effects of olanzapine and/or betahistine treatment (n=6/group) on [3H]ketansein 
binding to 5-HT2A receptors (nCi/mg tissue) in (A) the prefrontal cortex (PFC), (B) cingulate 
cortex (Cg), (C) caudate putamen (CPu), (D) nucleus accumbens, core (NAcC), (E) ventral 
tegmental area (VTA), and (F) substantia nigra (SN). Data shown are the mean values ± 
SEM. * p<0.05, ** p<0.01, *** p<0.001 vs. control. Abbreviations: Beta, betahistine; Olan, 
olanzapine; O+B, olanzapine and betahistine co-treatment. 
 
Figure 4 The effects of olanzapine and/or betahistine (n=6/group) on [³H]paroxetine binding 
to 5-HTT (nCi/mg tissue) in (A) the prefrontal cortex (PFC), (B) cingulate cortex (Cg), (C) 
caudate putamen (CPu), (D) nucleus accumbens, core (NAcC), (E) ventral tegmental area 
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(VTA), and (F) substantia nigra (SN). Data shown are the mean values ± SEM. * p<0.05, ** 
p<0.01 vs. control. Abbreviations are the same as in Figure 3. 
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